DexCom (DXCM) Stock Research, Analysis & News
Quick Analysis on DexCom (DXCM) Stock as of May 24, 2013
 | Previous Closing Price $20.27 is above 50 day moving average of $16.22 |
| Previous Closing Price $20.27 is above 200 day moving average of $14.52 |
 | The Stock pays no dividend |
| The closing price $20.27 is less than -9.62% away from its one year target price of $18.32 |
 | Current Short Ratio 16.80 is great than 1 |
| Earning per Share $-0.744 is negative. DexCom is lossing money. |
| EBITDA $-43.4M is negative |
(See more information about DexCom (DXCM) Stock below)
DexCom (DXCM) Stock Profile Summary
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes, and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The company offers FDA approved SEVEN, which includes a disposable sensor that can be inserted by a patient and used continuously for up to seven days; a transmitter; and a small handheld receiver. Its SEVEN system also received CE Mark approval for commercialization in the European Union and the countries in Asia and Latin America that recognize the CE Mark. The company also provides the SEVEN PLUS, which incorporates additional user interface and algorithm enhancements that are intended to make its glucose monitoring function customizable. Its SEVEN PLUS has FDA and CE Mark approvals. DexCom has a collaboration agreement with Edwards Lifesciences LLC to develop products for continuously monitoring blood glucose levels in patients hospitalized for various conditions. It also has development agreement with Insulet Corporation to integrate its continuous glucose monitoring technology into Insulets wireless, handheld OmniPod System Personal Diabetes Manager; and a joint development agreement with Animas Corporation to integrate its continuous glucose monitoring technology into Animas insulin pumps. The company was founded in 1999 and is headquartered in San Diego, California.
DexCom (DXCM) Stock Key Statistics Research and Analysis as of May 24, 2013
| Stock Exchange | NasdaqNM |
| Market Capitalization | $1.430B
|
| Trade Volume (Average Trading Volume) | 150,851 (367,018) |
| Price/Sales | 13.10 |
| Price/Book | 19.47 |
| Earning/Share | $-0.744 |
| Current Year EPS Estimate | $-0.56 |
| Next Year EPS Estimate | $-0.23 |
| Previous Closing Price | $20.27 |
| 50 Day Price Moving Average | $16.22 |
| 200 Day Price Moving Average | $14.52 |
| 1 yr Target Price | $18.32 |
| Short Ratio | 16.80 |
| EBITDA | $-43.4M |
DexCom (DXCM) Stock Competitor Research and Analysis
Mutual Funds with DexCom (DXCM) Stock in its top 10 holdings
Stock Research on DexCom (DXCM)
Latest Market News on DexCom (DXCM)
Click here to find the latest news on DexCom (DXCM)
Looking for Market Opportunties?
Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center
See other companies in the same industry
Medtronic, Inc. (MDT) Unitedhealth Group, Inc. (UNH) WellPoint Inc. (WLP) Aetna Inc. (AET)
Research on DexCom (DXCM)
